Deep Dives
New studies, trials, and what they mean.
A new class of Alzheimer’s drugs can modestly slow decline, but APOE4 carriers, especially homozygotes, face higher rates of a key side effect. How they work and what to weigh.
The landmark FINGER study tested whether a combined lifestyle program could protect cognition in at-risk older adults. What it found, the global trials it inspired, and why it matters for carriers.
For years, confirming Alzheimer’s biology meant a spinal tap or a PET scan. Blood tests are starting to change that. What they measure, where they stand, and the real caveats.
What if you could treat the gene itself? Researchers are exploring ways to target APOE directly, inspired by a remarkable protected patient. A grounded look at how early it still is.
Carriers are sought-after for prevention research. Why you might consider a trial, where to find one (including APOE-matched registries), and what to know before you enroll.
APOE4 headlines swing from "cure" to "doom" weekly. A practical toolkit for reading health studies and news so you can tell real signal from hype, and act on the right things.
In 4,392 healthy Taiwanese adults, APOE4 carriers declined faster on a thinking test after about age 70. A broader gene score did not.
A 2025 Brain study found APOE4 carriers show tau tangle spread at lower blood p-tau217, especially with two copies.
Early-pandemic data tied two-copy APOE4 to higher COVID-19 mortality, and COVID can affect the brain. Here is what is solid for carriers and what is still untested.
The first big Alzheimer's trial of a GLP-1 drug just reported. The honest answer about your brain is more nuanced than the hype or the backlash.
Halia's HT-4253 mimics a rare RAB10 variant that protects some APOE4 carriers. What the AAIC 2026 posters and Phase 2a trial actually show.
The Fortea 2024 study suggested APOE4/4 is a near-certain genetic form of Alzheimer's. Why sampling bias inflated that, and what the real penetrance is.
A heart-drug trial found a cholesterol pill slowed the rise of p-tau217, with the biggest shift in people who carry two APOE4 copies.
Tiny human pilots suggest the longevity drug rapamycin raises brain blood flow in middle-aged APOE4 carriers. Genotype-specific and exciting, and not ready to act on.
Vaccinated adults developed measurably less dementia in two strong natural experiments. For an APOE4 carrier, it may be a cheap, low-regret lever you are already due for.
A 2026 SPRINT analysis found intensive blood-pressure lowering prevented more dementia in APOE4 carriers than in non-carriers.
A 2,111-person US randomized trial just showed a structured lifestyle program protects thinking in at-risk older adults, and it enrolled the exact profile many carriers have.
What the APOLLOE4 Phase 3 trial of oral valiltramiprosate (ALZ-801) in APOE4/4 homozygotes actually showed: the miss, the MCI signal, no excess ARIA, and the p-tau217 data.